Roundhill GLP-1 & Weight Loss ETF
OZEM - ETF AI Analysis
Top Page
Roundhill GLP-1 & Weight Loss ETF (OZEM)
OZEM’s rating reflects a mix of strong, established pharmaceutical leaders and riskier early-stage biotech exposure in the weight-loss and GLP-1 space. Heavy positions in companies like Eli Lilly, Novo Nordisk, Pfizer, Amgen, and AstraZeneca support the fund through solid financial performance, positive earnings outlooks, and strategic growth initiatives, while smaller holdings such as Viking Therapeutics add potential upside but also higher risk due to losses and cash burn. The main risk factor is the fund’s concentration in a single, specialized healthcare theme, which can lead to higher volatility if sentiment or regulation around weight-loss and GLP-1 treatments changes.
OZEM vs. SPDR S&P 500 ETF (SPY)
- AUM
- 57.97M
- Region
- Global
- Expense Ratio
- 0.59%
- Beta
- 0.70
- Issuer
- Roundhill
- Inception Date
- May 21, 2024
- Dividend Yield
- 1.29%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
OZEM Summary
Roundhill GLP-1 & Weight Loss ETF (OZEM) is a healthcare-focused fund that invests in companies working on weight loss drugs and treatments, especially GLP-1 medicines used for obesity and related health issues. It doesn’t track a traditional index, but instead follows the theme of weight management and metabolic health. Top holdings include well-known drug makers like Eli Lilly and Novo Nordisk, plus other pharma and biotech firms in the U.S., Europe, and Asia. Someone might invest for growth potential as demand for weight loss treatments rises. A key risk is that it’s heavily concentrated in healthcare and can be very sensitive to drug news and regulation.
How much will it cost me?
This ETF has an expense ratio of 0.59%, which means you’ll pay about $5.90 per year for every $1,000 you invest. That’s higher than the average ETF because it’s a specialized, actively managed fund focused on a narrow niche in the healthcare and weight-loss sector.
What would affect this ETF?
This ETF is heavily focused on global healthcare and drug makers developing weight-loss and GLP-1 treatments, so it could benefit if demand for obesity and metabolic therapies keeps growing, new drugs are approved, and health systems or insurers expand coverage for these medicines. On the downside, it is concentrated in a few big names like Eli Lilly and Novo Nordisk, and could be hurt by stricter drug pricing rules, safety concerns, changing reimbursement policies, or a slowdown in innovation in this niche area.
OZEM Top 10 Holdings
OZEM is essentially a bet on the global weight-loss drug race, with Eli Lilly and Novo Nordisk sitting in the driver’s seat. Lilly has been rising steadily, helping power the fund, while Novo’s more mixed, recently lagging performance has taken a bit of shine off the story. Pfizer and Amgen add some steady, rising support, offsetting volatility from more speculative names like Viking Therapeutics, which has been dragging. With almost all exposure in healthcare and a global mix spanning the U.S., Europe, and Asia, this ETF is tightly focused on the GLP-1 and obesity-treatment theme.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co | 14.95% | $8.45M | $1.35T | 45.38% | 72Outperform |
 NVO | Novo Nordisk | 11.77% | $6.65M | $179.83B | -16.40% | 73Outperform |
 PFE | Pfizer | 8.04% | $4.55M | $167.35B | 15.44% | 74Outperform |
 HK:1093 | CSPC Pharmaceutical Group | 5.56% | $3.14M | HKD 98.98B | 12.83% | 63Neutral |
 KLRA | Kailera Therapeutics, Inc. | 5.50% | $3.11M | $1.85B | -44.69% | ―― |
 JP:4519 | Chugai Pharmaceutical Co | 5.33% | $3.01M | JPY 11.79T | -4.99% | 74Outperform |
 AMGN | Amgen | 4.76% | $2.69M | $251.65B | 38.31% | 77Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 VKTX | Viking Therapeutics | 4.32% | $2.44M | $3.65B | -29.95% | 53Neutral |
OZEM Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For OZEM, the sentiment is Positive. The current price of 31.73 is above the 20-day moving average (MA) of 30.32, above the 50-day MA of 30.71, and below the 200-day MA of 31.94, indicating a neutral trend. The MACD of 0.30 indicates Negative momentum. The RSI at 61.57 is Neutral, neither overbought nor oversold. The STOCH value of 93.85 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OZEM.
OZEM Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| OZEM | $31.73 | $31.00(-2.30% Downside) | $57.97M | 0.59% | 57Neutral |
 HRTS | $39.41 | $45.65(15.81% Upside) | $58.38M | 0.75% | 67Neutral |
 FMED | $32.76 | $48.94(49.37% Upside) | $30.57M | 0.50% | 59Neutral |
 MEDI | $36.25 | $46.27(27.62% Upside) | $44.21M | 0.80% | 62Neutral |
 PSIL | $20.07 | $53.80(168.06% Upside) | $43.64M | 1.00% | 44Neutral |
 TMED | $35.44 | $54.82(54.68% Upside) | $38.72M | 0.44% | 59Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| OZEM | Roundhill GLP-1 & Weight Loss ETF | 31.73 | 0.53 | 1.71% | |
| HRTS | Tema Cardiovascular and Metabolic ETF | 39.41 | 5.54 | 16.36% | |
| FMED | Fidelity Disruptive Medicine ETF | 32.76 | 5.81 | 21.55% | |
| MEDI | Harbor Health Care ETF | 36.25 | 5.29 | 17.10% | |
| PSIL | AdvisorShares Psychedelics ETF | 20.07 | 3.90 | 24.11% | |
| TMED | T. Rowe Price Health Care ETF | 35.44 | 6.35 | 21.83% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.